BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 16256161)

  • 1. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
    Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
    Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
    Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of immunodominant fragments from envelope gene for vaccine against Japanese encephalitis virus in DNA priming-protein boosting protocols.
    Chen CT; Yi YC; Chiang SC; Liu KC; Lin YL; Lee ST
    Microb Pathog; 2005; 38(2-3):53-62. PubMed ID: 15748807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smallpox subunit vaccine produced in Planta confers protection in mice.
    Golovkin M; Spitsin S; Andrianov V; Smirnov Y; Xiao Y; Pogrebnyak N; Markley K; Brodzik R; Gleba Y; Isaacs SN; Koprowski H
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6864-9. PubMed ID: 17428917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
    Gurt I; Abdalrhman I; Katz E
    Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.
    Lustig S; Maik-Rachline G; Paran N; Melamed S; Israely T; Erez N; Orr N; Reuveny S; Ordentlich A; Laub O; Shafferman A; Velan B
    Vaccine; 2009 Mar; 27(11):1691-9. PubMed ID: 19195492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune response to vaccinia virus is significantly reduced after scarification with TK- recombinants as compared to wild-type virus.
    Phillpotts RJ; Lescott T; Gates AJ; Jones L
    Acta Virol; 2000; 44(3):151-6. PubMed ID: 11155357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mousepox, a small animal model of smallpox.
    Esteban D; Parker S; Schriewer J; Hartzler H; Buller RM
    Methods Mol Biol; 2012; 890():177-98. PubMed ID: 22688768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.